NEUROCRINE BIOSCIENCES, INC.

Neurocrine Biosciences' Phase II trial of NBI-1070770 in 73 adults with major depressive disorder failed to meet its primary endpoint of reducing depression severity compared to placebo by day five.

Voyager Therapeutics introduced its Voyager NeuroShuttle platform, a nonviral delivery system that demonstrated sustained brain expression over three weeks in murine studies, significantly longer than transferrin receptor shuttles.

Neurocrine Biosciences will present expanded Phase 2 SAVITRI study data for osavampator, a first-in-class AMPA receptor modulator for major depressive disorder, at Psych Congress 2025.

The NHS in England has approved relugolix combination therapy as the first long-term daily oral treatment for endometriosis, expected to benefit around 1,000 women annually whose symptoms persist despite previous treatments.

Neurocrine Biosciences initiated Phase 1 trials for NBIP-01435, a long-acting injectable CRF1 receptor antagonist for congenital adrenal hyperplasia (CAH), complementing its recently approved oral therapy CRENESSITY.

Neurocrine Biosciences has launched a Phase 1 first-in-human clinical study evaluating NBIP-01435, a long-acting corticotropin-releasing factor type 1 receptor antagonist for congenital adrenal hyperplasia treatment.

Draig Therapeutics launched with $140 million in Series A funding to develop next-generation treatments for neuropsychiatric disorders, marking the largest commercial investment in Welsh research to date.

AbbVie has filed a new patent infringement lawsuit against Hetero Labs to prevent the production of generic versions of its endometriosis drug Orilissa (elagolix sodium).

Voyager Therapeutics published the first peer-reviewed study demonstrating alkaline phosphatase (ALPL) receptor's ability to transport novel AAV capsids across the blood-brain barrier in Molecular Therapy.

Neurocrine Biosciences, Madrigal Pharmaceuticals, and Vanda Therapeutics provided investors with key updates on their recent drug launches during Q1 earnings calls.